Levine, Ross L.

Publications

Sort by

Co-Author Network

selected publications

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Academic Article GET IT
Times cited: 278
PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation. Blood cancer discovery. 2022 Academic Article GET IT
Times cited: 5
The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasm. Blood. 2022 Academic Article GET IT
Times cited: 1
Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy. Blood advances. 2022 Academic Article GET IT
Times cited: 4
BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation. Blood. 2022 Academic Article GET IT
Times cited: 5
Challenges and opportunities for physician-scientists in advancing cancer research. Trends in cancer. 2022 Academic Article GET IT
Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022 Academic Article GET IT
Times cited: 12
De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features. Leukemia research. 2022 Academic Article GET IT
Times cited: 3
Targeting mutations in cancer. The Journal of clinical investigation. 2022 Review GET IT
Times cited: 21
Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 3
Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Academic Article GET IT
Times cited: 10
Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. Blood reviews. 2022 Review GET IT
Times cited: 1
Unlocking the secrets to Janus kinase activation. Science (New York, N.Y.). 2022 Comment GET IT
Times cited: 1
The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 ^low Mice. Frontiers in oncology. 2022 Academic Article GET IT
Times cited: 118
The hematopoietic saga of clonality in sickle cell disease. The Journal of clinical investigation. 2022 Comment GET IT
Times cited: 1
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022 Academic Article GET IT
Times cited: 13
Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome. HemaSphere. 2022 Academic Article GET IT
Times cited: 3
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. Cells. 2021 Academic Article GET IT
Times cited: 5
Clonal hematopoiesis is associated with risk of severe Covid-19. Nature communications. 2021 Academic Article GET IT
Times cited: 38
Aire regulates chromatin looping by evicting CTCF from domain boundaries and favoring accumulation of cohesin on superenhancers. Proceedings of the National Academy of Sciences of the United States of America. 2021 Academic Article GET IT
Times cited: 9
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood. 2021 Academic Article GET IT
Times cited: 36
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia. 2021 Academic Article GET IT
Times cited: 13
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Molecular cell. 2021 Academic Article GET IT
Times cited: 6
UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma. Life science alliance. 2021 Academic Article GET IT
Times cited: 5
A precision medicine classification for treatment of acute myeloid leukemia in older patients. Journal of hematology & oncology. 2021 Academic Article GET IT
Times cited: 3
A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML. Blood. 2021 Academic Article GET IT
Times cited: 2
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 6
The BAFfling story of MN1-induced leukemogenesis. Molecular cell. 2021 Comment GET IT
Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial. Therapeutic innovation & regulatory science. 2021 Academic Article GET IT
"Interferon" with MPN hematopoietic stem cells. Blood. 2021 Comment GET IT
Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood. 2021 Academic Article GET IT
Times cited: 42
The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. Cold Spring Harbor perspectives in medicine. 2021 Review GET IT
Times cited: 4
Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy. Leukemia research. 2021 Academic Article GET IT
DOT1L inhibitors block abnormal self-renewal induced by cohesin loss. Scientific reports. 2021 Academic Article GET IT
Times cited: 6
Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 8
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy. American journal of hematology. 2021 Letter GET IT
Times cited: 4
The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021 Academic Article GET IT
Times cited: 145
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021 Academic Article GET IT
Times cited: 35
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood advances. 2021 Academic Article GET IT
Times cited: 64
Toward More Complete Prognostication for Patients with Clonal Hematopoiesis. Blood cancer discovery. 2021 Comment GET IT
Times cited: 1
Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. Leukemia. 2021 Academic Article GET IT
Times cited: 6
LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer discovery. 2021 Academic Article GET IT
Times cited: 19
Clonal hematopoiesis before, during, and after human spaceflight. Cell reports. 2021 Article GET IT
Times cited: 4
Epigenetic Dysregulation of Myeloproliferative Neoplasms. Hematology/oncology clinics of North America. 2021 Review GET IT
Times cited: 2
The New Science and Concepts That Underlie Current and Future Treatments for Myeloproliferative Neoplasms. Hematology/oncology clinics of North America. 2021 Editorial Article GET IT
Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature communications. 2021 Academic Article GET IT
Times cited: 37
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. Nature immunology. 2021 Academic Article GET IT
Times cited: 17
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN. 2020 GET IT
Times cited: 3
Clonal hematopoiesis is associated with risk of severe Covid-19. medRxiv : the preprint server for health sciences. 2020 Article GET IT
Clonal Hematopoiesis Before, During, and After Human Spaceflight. Cell reports. 2020 Academic Article GET IT
Times cited: 15
Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020 Academic Article GET IT
Times cited: 192
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood advances. 2020 Academic Article GET IT
Times cited: 35
Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature genetics. 2020 Academic Article GET IT
Times cited: 221
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature medicine. 2020 Academic Article GET IT
Times cited: 66
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell reports. 2020 Academic Article GET IT
Times cited: 14
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs. Blood advances. 2020 Academic Article GET IT
Times cited: 2
Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML. Cancer discovery. 2020 Academic Article GET IT
Times cited: 14
Cancer did not stay home for COVID-19. Science advances. 2020 Editorial Article GET IT
Times cited: 1
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood reviews. 2020 Review GET IT
Times cited: 10
The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk Factor. JAMA cardiology. 2020 Academic Article GET IT
Times cited: 25
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2^V617F-Mutant MPN. Cancer discovery. 2020 Academic Article GET IT
Times cited: 33
Leukemia secondary to myeloproliferative neoplasms. Blood. 2020 Review GET IT
Times cited: 62
Loss of TET2 Affects Proliferation and Drug Sensitivity through Altered Dynamics of Cell-State Transitions. Cell systems. 2020 Academic Article GET IT
Times cited: 12
COVID-19 impact on early career investigators: a call for action. Nature reviews. Cancer. 2020 Academic Article GET IT
Times cited: 38
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition. Cancer discovery. 2020 Academic Article GET IT
Times cited: 17
Drug modulation by nuclear condensates. Science (New York, N.Y.). 2020 Comment GET IT
Times cited: 5
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. Blood advances. 2020 Academic Article GET IT
Times cited: 41
Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe^-/- Mice. Cardiovascular drugs and therapy. 2020 Academic Article GET IT
Times cited: 24
DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nature genetics. 2020 Academic Article GET IT
Times cited: 101
ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. Cell reports. 2020 Academic Article GET IT
Times cited: 11
Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures. Cell reports. 2020 Academic Article GET IT
Times cited: 4
Driver mutations in acute myeloid leukemia. Current opinion in hematology. 2020 Review GET IT
Times cited: 27
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science (New York, N.Y.). 2020 Academic Article GET IT
Times cited: 111
The Clinical Management of Clonal Hematopoiesis: Creation of a Clonal Hematopoiesis Clinic. Hematology/oncology clinics of North America. 2020 Review GET IT
Times cited: 32
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood. 2020 Academic Article GET IT
Times cited: 25
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature genetics. 2020 Academic Article GET IT
Times cited: 90
Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic Malignancies. Journal of the National Cancer Institute. 2020 Letter GET IT
Times cited: 8
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood advances. 2019 Academic Article GET IT
Times cited: 25
Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor. Blood advances. 2019 Academic Article GET IT
Times cited: 9
T cell-derived interferon-γ programs stem cell death in immune-mediated intestinal damage. Science immunology. 2019 Academic Article GET IT
Times cited: 63
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia. 2019 Academic Article GET IT
Times cited: 35
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019 Academic Article GET IT
Times cited: 114
Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. Blood advances. 2019 Academic Article GET IT
Times cited: 18
Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation. Cell stem cell. 2019 Academic Article GET IT
Times cited: 68
Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science translational medicine. 2019 Academic Article GET IT
Times cited: 42
Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. Haematologica. 2019 Letter GET IT
Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2019 Review GET IT
Times cited: 117
Challenges and approaches to implementing master/basket trials in oncology. Blood advances. 2019 Academic Article GET IT
Times cited: 8
Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes. Leukemia. 2019 Letter GET IT
Times cited: 4
Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 37
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer discovery. 2019 Academic Article GET IT
Times cited: 28
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer discovery. 2019 Academic Article GET IT
Times cited: 39
Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica. 2019 Academic Article GET IT
Times cited: 34
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer discovery. 2019 Academic Article GET IT
Times cited: 16
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 58
Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia. 2019 Academic Article GET IT
Times cited: 63
Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Review GET IT
Times cited: 13
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Academic Article GET IT
Times cited: 34
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood advances. 2018 Academic Article GET IT
Times cited: 47
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. Blood advances. 2018 Academic Article GET IT
Times cited: 31
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica. 2018 Academic Article GET IT
Times cited: 10
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2018 Academic Article GET IT
Times cited: 213
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. Haematologica. 2018 Letter GET IT
Times cited: 4
Targeting the CALR interactome in myeloproliferative neoplasms. JCI insight. 2018 Academic Article GET IT
Times cited: 42
Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 ^V617F Mice. Circulation research. 2018 Academic Article GET IT
Times cited: 131
Managing Clonal Hematopoiesis in Patients With Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 39
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA oncology. 2018 Academic Article GET IT
Times cited: 109
Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival. The Journal of clinical endocrinology and metabolism. 2018 Academic Article GET IT
Times cited: 26
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. 2018 GET IT
Times cited: 107
TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer discovery. 2018 Academic Article GET IT
Times cited: 101
HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer cell. 2018 Academic Article GET IT
Times cited: 69
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 5
Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Academic Article GET IT
Times cited: 85
Genetic and epigenetic determinants of AML pathogenesis. Seminars in hematology. 2018 Review GET IT
Times cited: 55
Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood. 2018 Academic Article GET IT
Times cited: 29
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia. 2018 Academic Article GET IT
Times cited: 37
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature medicine. 2018 Academic Article GET IT
Times cited: 121
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. 2018 GET IT
Times cited: 173
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood cancer journal. 2018 Academic Article GET IT
Times cited: 22
Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil. Stem cells (Dayton, Ohio). 2018 Review GET IT
Times cited: 51
LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. HemaSphere. 2018 Academic Article GET IT
Times cited: 63
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 60
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer cell. 2018 Academic Article GET IT
Times cited: 43
Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes & development. 2018 Academic Article GET IT
Times cited: 26
Cohesin mutations in myeloid malignancies made simple. Current opinion in hematology. 2018 Review GET IT
Times cited: 18
LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. 2018 Academic Article GET IT
Times cited: 69
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer discovery. 2018 Academic Article GET IT
Times cited: 47
Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. Cell stem cell. 2018 Review GET IT
Times cited: 274
Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis. Cell stem cell. 2018 Academic Article GET IT
Times cited: 4
TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis. Cell reports. 2018 Academic Article GET IT
Times cited: 50
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 56
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 2018 Academic Article GET IT
Times cited: 32
Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer cell. 2017 Academic Article GET IT
Times cited: 61
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer cell. 2017 Academic Article GET IT
Times cited: 137
Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. EBioMedicine. 2017 Academic Article GET IT
Times cited: 31
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. Haematologica. 2017 Letter GET IT
Times cited: 15
Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis. Cell stem cell. 2017 Academic Article GET IT
Times cited: 42
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell stem cell. 2017 Academic Article GET IT
Times cited: 435
TET2 in Normal and Malignant Hematopoiesis. Cold Spring Harbor perspectives in medicine. 2017 Review GET IT
Times cited: 58
Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 12
Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Current protocols in pharmacology. 2017 Review GET IT
Times cited: 12
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Academic Article GET IT
Times cited: 970
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017 Academic Article GET IT
Times cited: 262
Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature genetics. 2017 Academic Article GET IT
Times cited: 63
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer discovery. 2017 Academic Article GET IT
Times cited: 84
Efficacy of ALK5 inhibition in myelofibrosis. JCI insight. 2017 Academic Article GET IT
Times cited: 35
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 102
Cardiovascular disease: Commonality with cancer. Nature. 2017 Comment GET IT
Times cited: 17
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer discovery. 2017 Academic Article GET IT
Times cited: 82
Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis. PloS one. 2017 Academic Article GET IT
Times cited: 3
CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Science translational medicine. 2017 Academic Article GET IT
Times cited: 86
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 41
Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. Blood. 2017 Academic Article GET IT
Times cited: 16
Endothelial-specific inhibition of NF-κB enhances functional haematopoiesis. Nature communications. 2016 Academic Article GET IT
Times cited: 35
Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget. 2016 Academic Article GET IT
Times cited: 61
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016 Review GET IT
Times cited: 3568
An Unexpected Chink in the Transcriptional Armor of Plasmacytoid Dendritic Neoplasms. Cancer cell. 2016 Comment GET IT
Times cited: 3
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature medicine. 2016 Academic Article GET IT
Times cited: 169
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British journal of haematology. 2016 Academic Article GET IT
Times cited: 26
The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016 Academic Article GET IT
Times cited: 167
Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS). Leukemia research. 2016 Academic Article GET IT
Times cited: 25
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer cell. 2016 Academic Article GET IT
Times cited: 166
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. The Journal of experimental medicine. 2016 Academic Article GET IT
Times cited: 104
A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. Molecular cell. 2016 Academic Article GET IT
Times cited: 91
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leukemia research. 2016 Academic Article GET IT
Times cited: 13
LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis. Circulation research. 2016 Academic Article GET IT
Times cited: 53
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer cell. 2016 Academic Article GET IT
Times cited: 137
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Letter GET IT
Times cited: 27
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature medicine. 2016 Academic Article GET IT
Times cited: 246
A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI insight. 2016 Academic Article GET IT
Times cited: 706
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia. 2016 Academic Article GET IT
Times cited: 45
Roads Diverge--A Robert Frost View of Leukemia Development. The New England journal of medicine. 2016 Editorial Article GET IT
Times cited: 3
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature medicine. 2016 Letter GET IT
Times cited: 7
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 2016 Review GET IT
Times cited: 5
Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms. Cell & bioscience. 2016 Academic Article GET IT
Times cited: 1
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science signaling. 2016 Academic Article GET IT
Times cited: 50
Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. Haematologica. 2016 Letter GET IT
Times cited: 13
Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature. 2016 Academic Article GET IT
Times cited: 156
Acute myeloid leukaemia. Nature reviews. Disease primers. 2016 Review GET IT
Times cited: 213
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016 Academic Article GET IT
Times cited: 208
Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Haematologica. 2016 Review GET IT
Times cited: 35
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016 Academic Article GET IT
Times cited: 165
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Academic Article GET IT
Times cited: 102
Targeting a regulator of protein homeostasis in myeloproliferative neoplasms. Nature medicine. 2016 Comment GET IT
Times cited: 4
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia. 2015 Academic Article GET IT
Times cited: 53
Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. The Journal of experimental medicine. 2015 Academic Article GET IT
Times cited: 19
A Multiplexed System for Quantitative Comparisons of Chromatin Landscapes. Molecular cell. 2015 Academic Article GET IT
Times cited: 73
Molecular therapy for acute myeloid leukaemia. Nature reviews. Clinical oncology. 2015 Review GET IT
Times cited: 100
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell reports. 2015 Academic Article GET IT
Times cited: 45
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. eLife. 2015 Academic Article GET IT
Times cited: 96
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature medicine. 2015 Academic Article GET IT
Times cited: 118
Defining ATM-Independent Functions of the Mre11 Complex with a Novel Mouse Model. Molecular cancer research : MCR. 2015 Academic Article GET IT
Times cited: 6
Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. Annual review of medicine. 2015 Review GET IT
Times cited: 38
Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia. Experimental hematology. 2015 Review GET IT
Times cited: 22
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015 Academic Article GET IT
Times cited: 29
Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. The Journal of experimental medicine. 2015 Academic Article GET IT
Times cited: 112
Loss of BAP1 function leads to EZH2-dependent transformation. Nature medicine. 2015 Academic Article GET IT
Times cited: 253
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 245
Next-Generation Sequencing and Detection of Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Clinical Practice?. JAMA. 2015 Editorial Article GET IT
Times cited: 14
Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015 Academic Article GET IT
Times cited: 486
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic proceedings. 2015 Academic Article GET IT
Times cited: 122
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer cell. 2015 Academic Article GET IT
Times cited: 110
Somatic mutations in leukocytes infiltrating primary breast cancers. NPJ breast cancer. 2015 Academic Article GET IT
Times cited: 21
Stem Cells and Aging: What's Next?. Cell stem cell. 2015 Academic Article GET IT
Times cited: 8
Central role of ULK1 in type I interferon signaling. Cell reports. 2015 Academic Article GET IT
Times cited: 55
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer cell. 2015 Academic Article GET IT
Times cited: 170
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Review GET IT
Times cited: 25
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia. 2015 Letter GET IT
Times cited: 46
Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. Blood. 2015 Academic Article GET IT
Times cited: 66
IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour. Cancer cell. 2015 Comment GET IT
Times cited: 3
The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells. Stem cell reports. 2015 Academic Article GET IT
Times cited: 4
Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 76
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia. 2015 Academic Article GET IT
Times cited: 41
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer discovery. 2015 Academic Article GET IT
Times cited: 212
The role of mutations in epigenetic regulators in myeloid malignancies. Immunological reviews. 2015 Review GET IT
Times cited: 43
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell reports. 2014 Academic Article GET IT
Times cited: 206
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 209
Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2014 Academic Article GET IT
Times cited: 80
Dynamic evolution of clonal epialleles revealed by methclone. Genome biology. 2014 Academic Article GET IT
Times cited: 50
Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood. 2014 Academic Article GET IT
Times cited: 43
Integrating genomics into prognostic models for AML. Seminars in hematology. 2014 Academic Article GET IT
Times cited: 6
Translational implications of somatic genomics in acute myeloid leukaemia. The Lancet. Oncology. 2014 Review GET IT
Times cited: 101
Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation. Journal of leukemia (Los Angeles, Calif.). 2014 Academic Article GET IT
A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Best practice & research. Clinical haematology. 2014 Review GET IT
Times cited: 17
Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data. The Journal of molecular diagnostics : JMD. 2014 Academic Article GET IT
Times cited: 24
Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood. 2014 Academic Article GET IT
Times cited: 167
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 45
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. Leukemia. 2014 Letter GET IT
Times cited: 11
Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PloS one. 2014 Academic Article GET IT
Times cited: 27
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014 Academic Article GET IT
Times cited: 310
Tumor heterogeneity confounds and illuminates: assessing the implications. Nature medicine. 2014 Academic Article GET IT
Times cited: 91
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. 2014 GET IT
Times cited: 67
HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. The Journal of clinical investigation. 2014 Review GET IT
Times cited: 33
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Review GET IT
Times cited: 128
Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: a case series with molecular genetic analysis and review of the literature. Leukemia & lymphoma. 2014 Review GET IT
Times cited: 16
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 2014 Academic Article GET IT
Times cited: 89
Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. The Journal of clinical investigation. 2014 Academic Article GET IT
Times cited: 51
A WIMSical approach to decoding DNA methylation in myeloid leukemia. Genome biology. 2014 Comment GET IT
Times cited: 1
Genetics of myeloproliferative neoplasms. Cancer journal (Sudbury, Mass.). 2014 Review GET IT
Times cited: 46
Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell reports. 2013 Academic Article GET IT
Times cited: 84
Another piece of the myeloproliferative neoplasms puzzle. The New England journal of medicine. 2013 Editorial Article GET IT
Times cited: 13
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell reports. 2013 Academic Article GET IT
Times cited: 96
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 254
Mining the epigenetic landscape in ALL. Nature genetics. 2013 Comment GET IT
Times cited: 2
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. The Journal of clinical investigation. 2013 Academic Article GET IT
Times cited: 54
Molecular pathogenesis of AML: translating insights to the clinic. Best practice & research. Clinical haematology. 2013 Review GET IT
Times cited: 15
Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells. Physical biology. 2013 Academic Article GET IT
Times cited: 6
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature genetics. 2013 Academic Article GET IT
Times cited: 224
Isocitrate dehydrogenase mutations in leukemia. The Journal of clinical investigation. 2013 Review GET IT
Times cited: 54
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013 Academic Article GET IT
Times cited: 96
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 2013 Letter GET IT
Times cited: 101
Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. American journal of hematology. 2013 Academic Article GET IT
Times cited: 18
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013 Academic Article GET IT
Times cited: 162
Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013 Academic Article GET IT
Times cited: 131
Advances in the development of animal models of myeloid leukemias. Seminars in hematology. 2013 Review GET IT
Times cited: 3
AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013 Academic Article GET IT
Times cited: 54
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. International journal of hematology. 2013 Review GET IT
Times cited: 31
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer cell. 2013 Academic Article GET IT
Times cited: 608
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013 Review GET IT
Times cited: 206
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013 Academic Article GET IT
Times cited: 159
Leveraging cancer genome information in hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Review GET IT
Times cited: 12
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nature medicine. 2013 Academic Article GET IT
Times cited: 144
An optimized algorithm for detecting and annotating regional differential methylation. BMC bioinformatics. 2013 Academic Article GET IT
Times cited: 88
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. 2013 Academic Article GET IT
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nature medicine. 2013 Academic Article GET IT
Times cited: 175
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer discovery. 2013 Academic Article GET IT
Times cited: 116
Vascular endothelial growth factor expression in acute myeloid leukemia: a biomarker ready for primetime?. Leukemia & lymphoma. 2013 Comment GET IT
Times cited: 1
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nature genetics. 2013 Academic Article GET IT
Times cited: 228
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 127
TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. The EMBO journal. 2013 Academic Article GET IT
Times cited: 361
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013 Academic Article GET IT
Times cited: 94
HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 40
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. The Journal of biological chemistry. 2012 Academic Article GET IT
Times cited: 125
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2012 Academic Article GET IT
Times cited: 56
Progression of RAS-mutant leukemia during RAF inhibitor treatment. 2012 GET IT
Times cited: 197
Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia. 2012 GET IT
Times cited: 3
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leukemia research. 2012 Academic Article GET IT
Times cited: 27
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature genetics. 2012 Academic Article GET IT
Times cited: 614
Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. British journal of cancer. 2012 Academic Article GET IT
Times cited: 88
JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends in pharmacological sciences. 2012 Review GET IT
Times cited: 61
IDH1 mutations disrupt blood, brain, and barriers. Cancer cell. 2012 Academic Article GET IT
Times cited: 8
Do circulating tumor cells play a role in coagulation and thrombosis?. Frontiers in oncology. 2012 Academic Article GET IT
Times cited: 15
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Academic Article GET IT
Times cited: 281
Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature. 2012 Academic Article GET IT
Times cited: 304
Non-CML myeloproliferative diseases. Preface. Hematology/oncology clinics of North America. 2012 Editorial Article GET IT
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. 2012 GET IT
Times cited: 43
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematology/oncology clinics of North America. 2012 Review GET IT
Times cited: 23
The role of mutations in epigenetic regulators in myeloid malignancies. Nature reviews. Cancer. 2012 Review GET IT
Times cited: 562
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer cell. 2012 Academic Article GET IT
Times cited: 455
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer cell. 2012 Academic Article GET IT
Times cited: 543
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (New York, N.Y.). 2012 Academic Article GET IT
Times cited: 307
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 383
miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia. 2012 Academic Article GET IT
Times cited: 48
Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell stem cell. 2012 Academic Article GET IT
Times cited: 195
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012 Academic Article GET IT
Times cited: 78
New pieces of a puzzle: the current biological picture of MPN. Biochimica et biophysica acta. 2012 Review GET IT
Times cited: 8
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leukemia & lymphoma. 2012 Letter GET IT
Times cited: 19
Genetic profiling in acute myeloid leukemia. The New England journal of medicine. 2012 Letter GET IT
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer discovery. 2012 Academic Article GET IT
Times cited: 95
Targeting β-catenin in CML: leukemia stem cells beware!. Cell stem cell. 2012 Comment GET IT
Times cited: 13
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012 Academic Article GET IT
Times cited: 179
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 1497
DNMT3A and stem cell function: new insights into old pathways. Haematologica. 2012 Article GET IT
Times cited: 3
Targeted immunotherapy for hairy cell leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Comment GET IT
Times cited: 5
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Academic Article GET IT
Times cited: 1461
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012 Academic Article GET IT
Times cited: 1441
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nature medicine. 2012 Academic Article GET IT
Times cited: 403
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. The Journal of experimental medicine. 2012 Academic Article GET IT
Times cited: 129
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS computational biology. 2012 Academic Article GET IT
Times cited: 52
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?. Hematology. American Society of Hematology. Education Program. 2012 Review GET IT
Times cited: 37
JAK-mutant myeloproliferative neoplasms. Current topics in microbiology and immunology. 2012 Review GET IT
Times cited: 19
Nuclear JAK2. Blood. 2011 Letter GET IT
Times cited: 7
Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood cancer journal. 2011 Academic Article GET IT
Times cited: 24
Clinical implications of novel mutations in epigenetic modifiers in AML. Hematology/oncology clinics of North America. 2011 Review GET IT
Times cited: 40
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2011 Academic Article GET IT
Times cited: 72
The spliceosome as an indicted conspirator in myeloid malignancies. Cancer cell. 2011 Comment GET IT
Times cited: 38
Molecular biology of myelodysplastic syndromes. Seminars in oncology. 2011 Review GET IT
Times cited: 26
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene. 2011 Academic Article GET IT
Times cited: 154
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature chemical biology. 2011 Academic Article GET IT
Times cited: 213
Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood. 2011 Academic Article GET IT
Times cited: 74
TET family proteins and their role in stem cell differentiation and transformation. Cell stem cell. 2011 Review GET IT
Times cited: 190
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2011 Academic Article GET IT
Times cited: 31
JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?. Therapeutic advances in hematology. 2011 Academic Article GET IT
Times cited: 2
Clinical effect of point mutations in myelodysplastic syndromes. The New England journal of medicine. 2011 Academic Article GET IT
Times cited: 1241
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer cell. 2011 Academic Article GET IT
Times cited: 970
Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood. 2011 Academic Article GET IT
Times cited: 34
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011 Academic Article GET IT
Times cited: 302
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. The Journal of biological chemistry. 2011 Academic Article GET IT
Times cited: 39
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. 2011 Letter GET IT
Times cited: 117
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011 Letter GET IT
Times cited: 177
Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models. The Journal of clinical investigation. 2011 Comment GET IT
Times cited: 3
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood cancer journal. 2011 Academic Article GET IT
Times cited: 11
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer cell. 2011 Academic Article GET IT
Times cited: 196
Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Review GET IT
Times cited: 265
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica. 2010 Letter GET IT
Times cited: 18
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell. 2010 Academic Article GET IT
Times cited: 2085
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 2010 Academic Article GET IT
Times cited: 87
PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2010 Academic Article GET IT
Times cited: 36
Metabolic syndromes and malignant transformation: where the twain shall meet. Science translational medicine. 2010 Academic Article GET IT
Times cited: 2
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes & development. 2010 Academic Article GET IT
Times cited: 156
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 95
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer cell. 2010 Academic Article GET IT
Times cited: 224
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. The Journal of clinical investigation. 2010 Academic Article GET IT
Times cited: 152
Recent advances in the treatment of acute myeloid leukemia. F1000 medicine reports. 2010 Academic Article GET IT
Times cited: 1336
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 30
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010 Letter GET IT
Times cited: 64
Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Blood. 2010 Academic Article GET IT
Times cited: 41
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010 Academic Article GET IT
Times cited: 263
Metabolism and the leukemic stem cell. The Journal of experimental medicine. 2010 Comment GET IT
Times cited: 65
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer cell. 2010 Academic Article GET IT
Times cited: 1554
The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Academic Article GET IT
Times cited: 2749
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood. 2010 Academic Article GET IT
Times cited: 64
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer research. 2010 Academic Article GET IT
Times cited: 255
Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. American journal of hematology. 2010 Letter GET IT
Times cited: 21
Mechanisms of mutations in myeloproliferative neoplasms. Best practice & research. Clinical haematology. 2009 Review GET IT
Times cited: 15
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009 Academic Article GET IT
Times cited: 149
A progenitor cell origin of myeloid malignancies. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 43
Mutation in TET2 in myeloid cancers. The New England journal of medicine. 2009 Letter GET IT
Times cited: 48
Inherited susceptibility to pediatric acute lymphoblastic leukemia. Nature genetics. 2009 Article GET IT
Times cited: 8
A common genetic mechanism in malignant bone marrow diseases. The New England journal of medicine. 2009 Editorial Article GET IT
Times cited: 14
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Academic Article GET IT
Times cited: 572
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. 2009 Academic Article GET IT
Times cited: 76
Janus kinase mutations. Seminars in oncology. 2009 Academic Article GET IT
Times cited: 6
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009 Letter GET IT
Times cited: 218
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. The Journal of clinical investigation. 2009 Academic Article GET IT
Times cited: 90
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nature genetics. 2009 Academic Article GET IT
Times cited: 278
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009 Academic Article GET IT
Times cited: 205
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 Academic Article GET IT
Times cited: 347
Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood. 2009 Academic Article GET IT
Times cited: 71
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Review GET IT
Times cited: 5
Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annual review of medicine. 2009 Review GET IT
Times cited: 81
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 2008 Academic Article GET IT
Times cited: 98
Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia. 2008 Academic Article GET IT
Times cited: 29
Myeloproliferative disorders. Blood. 2008 Review GET IT
Times cited: 252
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008 Review GET IT
Times cited: 92
Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia. 2008 Letter GET IT
Times cited: 23
Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Experimental hematology. 2008 Academic Article GET IT
Times cited: 37
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer research. 2008 Academic Article GET IT
Times cited: 175
JAK2 and MPL mutations in myeloproliferative neoplasms. Acta haematologica. 2008 Review GET IT
Times cited: 8
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Molecular cancer therapeutics. 2008 Academic Article GET IT
Times cited: 41
JAK2V617F: you can't have too much. Blood. 2008 Comment GET IT
Times cited: 5
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer cell. 2008 Academic Article GET IT
Times cited: 313
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008 Academic Article GET IT
Times cited: 83
Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation. Leukemia. 2008 Letter GET IT
Times cited: 8
New advances in the pathogenesis and therapy of essential thrombocythemia. Hematology. American Society of Hematology. Education Program. 2008 Review GET IT
Times cited: 8
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer cell. 2007 Academic Article GET IT
Times cited: 159
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Current opinion in oncology. 2007 Review GET IT
Times cited: 8
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer cell. 2007 Academic Article GET IT
Times cited: 168
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature reviews. Cancer. 2007 Review GET IT
Times cited: 448
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2007 Letter GET IT
Times cited: 382
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. American journal of human genetics. 2007 Academic Article GET IT
Times cited: 211
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007 Academic Article GET IT
Times cited: 223
Utilization of self-expanding stents in the treatment of intracranial atherosclerotic disease in the distal small cerebral vessels. 2007 GET IT
Times cited: 15
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England journal of medicine. 2007 Academic Article GET IT
Times cited: 1015
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia research. 2007 Conference Paper GET IT
Times cited: 243
JAK-2 mutations and their relevance to myeloproliferative disease. Current opinion in hematology. 2007 Review GET IT
Times cited: 53
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. British journal of haematology. 2006 Academic Article GET IT
Times cited: 85
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 64
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Academic Article GET IT
Times cited: 854
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS medicine. 2006 Academic Article GET IT
Times cited: 1134
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood. 2006 Academic Article GET IT
Times cited: 96
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006 Academic Article GET IT
Times cited: 410
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood. 2006 Letter GET IT
Times cited: 54
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006 Academic Article GET IT
Times cited: 207
Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology. American Society of Hematology. Education Program. 2006 Review GET IT
Times cited: 56
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proceedings of the National Academy of Sciences of the United States of America. 2005 Academic Article GET IT
Times cited: 259
Genetics of myeloid malignancies: pathogenetic and clinical implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Review GET IT
Times cited: 299
The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. British journal of haematology. 2005 Letter GET IT
Times cited: 49
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005 Academic Article GET IT
Times cited: 321
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005 Academic Article GET IT
Times cited: 415
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer cell. 2005 Academic Article GET IT
Times cited: 2496
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005 Academic Article GET IT
Times cited: 59
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nature genetics. 2004 Academic Article GET IT
Times cited: 346
Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma. 2003 GET IT
Times cited: 2
Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2000 Academic Article GET IT
Times cited: 89
MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene. 1998 Academic Article GET IT
Times cited: 434
PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer research. 1998 Academic Article GET IT
Times cited: 236
p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. The American journal of pathology. 1997 Academic Article GET IT
Times cited: 344

more ...

less ...

Background

education and training

M.D., The Johns Hopkins University School of Medicine 1999
A.B., Harvard College 1994

Contact

full name

Ross L. Levine

primary email

leviner@mskcc.org

VIVO Weill Cornell Medical College

Ross L. Levine Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email